Cargando…
Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high‐binding affinity for the PSMA receptor have allowed high quality, highly specific PET ima...
Autores principales: | Emmett, Louise, Willowson, Kathy, Violet, John, Shin, Jane, Blanksby, Ashley, Lee, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355374/ https://www.ncbi.nlm.nih.gov/pubmed/28303694 http://dx.doi.org/10.1002/jmrs.227 |
Ejemplares similares
-
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020) -
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020) -
Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022) -
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023) -
Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
por: Crumbaker, Megan, et al.
Publicado: (2023)